April 20, 2018 11:11 AM ET


Company Overview of vasopharm GmbH

Company Overview

vasopharm GmbH discovers and develops therapeutics for the treatment of cerebro and cardiovascular diseases, and their consequences. The company primarily focuses on drug development in acute niche indications with an unmet medical need that enables to demonstrate clinical efficacy. Its therapeutic pipeline includes VAS203, an allosteric nitric oxide synthase inhibitor interacting with the BH4 binding site of the enzyme for the treatment of traumatic brain injury; and VAS2870, a NAD(P)H oxidase (NOX) modulator for the treatment of peripheral arterial occlusive diseases. The company was founded in 1998 and is based in Wurzburg, Germany.

Friedrich-Bergius-Ring 15

Wurzburg,  97076


Founded in 1998


49 931 35 90 99 0


49 931 35 90 99 12

Key Executives for vasopharm GmbH

Co-Founder and Chief Executive Officer
Co-Founder and Clinical & Scientific Advisor
Chief Scientific Officer and Managing Director
Compensation as of Fiscal Year 2017.

vasopharm GmbH Key Developments

vasopharm GmbH Presents at 3rd Annual Neuroscience BioPartnering & Investment Forum, Mar-20-2018

vasopharm GmbH Presents at 3rd Annual Neuroscience BioPartnering & Investment Forum, Mar-20-2018 . Venue: New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, New York, United States.

Vasopharm GmbH Provides Update on Phase III Traumatic Brain Injury Trial

Vasopharm GmbH announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III clinical trial. This milestone triggers an interim review by the Data Monitoring Committee in line with the agreed study protocol. Allowing for the six month extended Glasgow Outcome Scale evaluation for the 110th eligible patient recruited, The company expects feedback from the DMC in Fourth Quarter 2018. NOSTRA III is designed to assess the efficacy and safety of Ronopterin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain injury patients, for which there is no existing drug treatment. Traumatic Brain Injury is the leading cause of death and disability among young adults in the developed world. Annually, within the US alone, head trauma is the cause of about two million emergency room visits, roughly 475,000 hospital admissions, nearly 52,000 deaths and approximately 80,000 cases of severe long-term disability. Direct costs attributed to the treatment of TBI exceed $10 billion p.a. in the US alone. NOSTRA III is a randomised, double-blind, placebo-controlled trial. The study will enroll 220 patients who have suffered a moderate to severe TBI resulting in hospitalisation and who have received an intra-cranial pressure probe. Currently, 35 European neuro-trauma centres in Germany, Austria, France, UK and Spain are participating. The primary endpoint is the eGOS evaluated at six months after the injury. Secondary efficacy assessments include Quality of Life as well as Therapy Intensity Level over 14 days after brain injury. NOSTRA III is a registration trial which seeks to validate the data from the highly significant NOSTRA II trial. The study aims to confirm the data from a Phase II trial in which VAS203 has shown a improvement in the extended Glasgow Outcomes Score.

vasopharm GmbH Presents at 2nd Annual Neuroscience BioPartnering & Investment Forum, Mar-27-2017 02:05 PM

vasopharm GmbH Presents at 2nd Annual Neuroscience BioPartnering & Investment Forum, Mar-27-2017 02:05 PM. Venue: 7 World Trade Center, 250 Greenwich St., 40th Floor (D Elevator Bank), The New York Academy of Sciences, New York, NY 10007, United States.

Similar Private Companies By Industry

Company Name Region
µ-bond GmbH Europe
4 Animals AlsterScience GmbH Europe
Acousia Therapeutics GmbH Europe
Across Barriers GmbH Europe
Actinodrug Pharmaceuticals GmbH Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact vasopharm GmbH, please visit www.vasopharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.